

March 20, 2018

Life Science Institute, Inc.

Establishment of Cell Processing Center for Muse Cell Products

Life Science Institute, Inc. (Head Office: Chiyoda-ku, Tokyo, President: Seiichi Kiso, hereinafter referred to as “LSII”), a group company of Mitsubishi Chemical Holdings Corporation, is pleased to announce that LSII has decided to establish a Cell Processing Center (hereinafter referred to as “CPC”) in the Life Innovation Center (Kawasaki-shi, Kanagawa).

LSII has been promoting the research and development of regenerative medicine products using Muse cells. LSII began clinical trials to treat acute myocardial infarction in January, 2018 and aims to obtain approval in the fiscal 2021. The CPC that will be newly established is planned to be used for the manufacturing of Muse cell products used for clinical trials and their commercial manufacturing after the approval.

LSII will promote research and development to deliver high-quality Muse cell products to patients as soon as possible.

[Overview of the facility]

Name	LSII Regenerative Medicine Center (tentative name)
Address	Life Innovation Center, 3-25-22, Tono-machi, Kawasaki-ku, Kawasaki-shi, Kanagawa, Japan
Total floor area	1,267.5 m ²
Schedule	Start of construction: May 2018 Completion: September 2018 Start of operation: January 2019